Notícias/Reuters/Glenmark Pharma Says Unit IGI Submits IND Application To U.S. FDA For ISB 2301 Targeting Solid TumorsGlenmark Pharma Says Unit IGI Submits IND Application To U.S. FDA For ISB 2301 Targeting Solid TumorsLer o artigo completoTenha acesso ilimitado aos artigos da Reuters e de todas as outras fontes de notícias no TradingView.Continue lendo